The stock of Bluebird bio Inc (BLUE) has gone up by 8.33% for the week, with a 30.18% rise in the past month and a 33.83% rise in the past quarter. The volatility ratio for the week is 9.73%, and the volatility levels for the past 30 days are 9.32% for BLUE. The simple moving average for the past 20 days is 11.84% for BLUE’s stock, with a -26.57% simple moving average for the past 200 days.
Is It Worth Investing in Bluebird bio Inc (NASDAQ: BLUE) Right Now?
Moreover, the 36-month beta value for BLUE is 0.80. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BLUE is 189.84M and currently, short sellers hold a 16.21% of that float. On July 29, 2024, BLUE’s average trading volume was 6.12M shares.
BLUE) stock’s latest price update
The stock of Bluebird bio Inc (NASDAQ: BLUE) has increased by 1.23 when compared to last closing price of 1.22. Despite this, the company has experienced a 8.33% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-07-12 that NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company.
Analysts’ Opinion of BLUE
Morgan Stanley, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $7, previously predicting the price at $3. The rating they have provided for BLUE stocks is “Equal-Weight” according to the report published on December 08th, 2023.
BLUE Trading at 21.49% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.67% of loss for the given period.
Volatility was left at 9.32%, however, over the last 30 days, the volatility rate increased by 9.73%, as shares surge +23.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.02% upper at present.
During the last 5 trading sessions, BLUE rose by +7.02%, which changed the moving average for the period of 200-days by -59.47% in comparison to the 20-day moving average, which settled at $1.1161. In addition, Bluebird bio Inc saw -10.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLUE starting from Klima Thomas J, who sale 3,834 shares at the price of $0.97 back on Jun 03 ’24. After this action, Klima Thomas J now owns 121,006 shares of Bluebird bio Inc, valued at $3,726 using the latest closing price.
Obenshain Andrew, the President and CEO of Bluebird bio Inc, sale 6,095 shares at $1.53 during a trade that took place back on Mar 04 ’24, which means that Obenshain Andrew is holding 279,998 shares at $9,311 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -7.46 for the present operating margin
- -0.1 for the gross margin
The net margin for Bluebird bio Inc stands at -5.11. The total capital return value is set at -0.36. Equity return is now at value -47.81, with -16.08 for asset returns.
Based on Bluebird bio Inc (BLUE), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 1.36. The interest coverage ratio of the stock is 1.72.
Currently, EBITDA for the company is -277.21 million with net debt to EBITDA at -0.55. When we switch over and look at the enterprise to sales, we see a ratio of 17.29. The receivables turnover for the company is 0.94for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.55.
Conclusion
To wrap up, the performance of Bluebird bio Inc (BLUE) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
